Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 initiation79d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

Therapy area: Oncology. Indication: Solid Tumor

Apr 30, 2026phase 1 initiation79d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 1 initiation79d agoVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)nivolumab

Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Oral Cavity (Mouth) Cancer, Squamous Cell Carcinoma

full page →nivolumab →source: globaldata

Apr 30, 2026phase 1 initiation79d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

full page →GS-1701 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoJiangsu Vcare PharmaTech Co Ltd — VC-005 (Phase I Trial Initiation)VC-005

Therapy area: Dermatology. Indication: Atopic Dermatitis (Atopic Eczema)

full page →VC-005 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoChiral Biotech Pharma Pty Ltd — esketamine hydrochloride (Phase I Trial Initiation)esketamine hydrochloride

Therapy area: Central Nervous System. Indication: Treatment Resistant Depression

full page →esketamine hydrochloride →source: globaldata

Apr 30, 2026phase 1 initiation79d agoMerck & Co Inc — MK-6050 (Phase I Trial Initiation)MK-6050

Therapy area: Dermatology. Indication: Hidradenitis Suppurativa

full page →MK-6050 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoGan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)GLR-2037

Therapy area: Oncology. Indication: Prostate Cancer

full page →GLR-2037 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoBeijing Continent Pharmaceutical Co Ltd — F-351 (Phase I Trial Initiation)F-351

Therapy area: Gastrointestinal. Indication: Liver Fibrosis

full page →F-351 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

full page →DAPAGLIFLOZIN →source: globaldata

Apr 30, 2026phase 1 initiation79d agoAvance Clinical Pty Ltd — ZE-740282 (Phase I Trial Initiation)ZE-740282

Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myeloproliferative Disorders, Polycythemia Vera

full page →ZE-740282 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoByterna Therapeutics Ltd — BR-101 (Phase I Trial Initiation)BR-101

Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

full page →BR-101 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoBristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)navlimetostat

Therapy area: Oncology. Indication: Biliary Tumor, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

full page →navlimetostat →source: globaldata

Apr 30, 2026phase 1 initiation79d agoShanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)HLX-3901

Therapy area: Oncology. Indication: Neuroendocrine Carcinoma, Small-Cell Lung Cancer

full page →HLX-3901 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoCentre Hospitalier Universitaire de Nice — Leucogenase (Phase I Trial Initiation)Leucogenase

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

full page →Leucogenase →source: globaldata

Apr 30, 2026phase 1 initiation79d agoJiangsu Hansoh Pharmaceutical Group Co Ltd — HS-10506 (Phase I Trial Initiation)HS-10506

Therapy area: Central Nervous System. Indication: Depression, Insomnia

full page →HS-10506 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoKexing Biopharm Co Ltd — GB-18 (Phase I Trial Initiation)GB-18

Therapy area: Musculoskeletal Disorders, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cachexia, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor, Unspecified Cancer

full page →GB-18 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoBeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)BGC-0979

Therapy area: Oncology. Indication: Solid Tumor

full page →BGC-0979 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

full page →IASO-782 →source: globaldata

Apr 30, 2026phase 1 initiation79d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →DASATINIB →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoBeijing Tiantan Hospital — XS-411 (Phase I/II Trial Completion)XS-411

Therapy area: Central Nervous System. Indication: Parkinson's Disease

full page →XS-411 →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoAbbVie Inc — blinatumomab (Phase I/II Trial Completion)blinatumomab

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

full page →blinatumomab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoBellicum Pharmaceuticals Inc — acetaminophen (Phase I/II Trial Completion)acetaminophen ER

Therapy area: Oncology. Indication: Breast Cancer, Lung Cancer, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoIRCCS Foundation National Cancer Institute — bevacizumab (Phase I/II Trial Completion)bevacizumab

Therapy area: Oncology. Indication: Metastatic Colorectal Cancer

full page →bevacizumab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoZhongshan Hospital — iNKT Cell Immunotherapy (Phase I/II Trial Completion)iNKT Cell Immunotherapy

Therapy area: Oncology. Indication: Bladder Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

full page →iNKT Cell Immunotherapy →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoNovartis AG — zigakibart (Phase I/II Trial Completion)zigakibart

Therapy area: Genito Urinary System. Indication: IgA Nephropathy (Berger's Disease)

full page →zigakibart →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoAmsterdam UMC — tremelimumab (Phase I/II Trial Completion)tremelimumab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →tremelimumab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoInstitute of Hematology & Blood Diseases Hospital — cyclophosphamide (Phase I/II Trial Completion)cyclophosphamide

Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

full page →cyclophosphamide →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoZhejiang Doer Biologics Corp — DR-30206 (Phase I/II Trial Completion)DR-30206

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Cancer, Gastrointestinal Tumor, Metastatic Colorectal Cancer

full page →DR-30206 →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoUnity Health Toronto — bupivacaine (Phase I/II Trial Completion)bupivacaine

Therapy area: Musculoskeletal Disorders. Indication: Osteoarthritis

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoHenan Provincial People's Hospital — ofatumumab (Phase I/II Trial Completion)ofatumumab

Therapy area: Central Nervous System. Indication: Neuromyelitis Optica (Devic's Syndrome)

full page →ofatumumab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoDuke University — deferiprone (Phase I/II Trial Completion)deferiprone

Therapy area: Cardiovascular, Central Nervous System. Indication: Cerebral Aneurysms, Dementia, Stroke, Subarachnoid Hemorrhage

full page →deferiprone →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoLepu Biopharma Co Ltd — pucotenlimab (Phase I/II Trial Completion)pucotenlimab

Therapy area: Oncology. Indication: Pancreatic Cancer

full page →pucotenlimab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoJiangsu Hengrui Pharmaceuticals Co Ltd — adebrelimab (Phase I/II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoMultitude therapeutics Inc — AMT-253 (Phase I/II Trial Completion)AMT-253

Therapy area: Non Malignant Disorders, Oncology. Indication: Acral Lentiginous Melanoma, Cervical Cancer, Endometrial Cancer, Gynecological Cancer, Leiomyosarcoma, Melanoma, Metastatic Melanoma, Solid Tumor, Uterine Leiomyoma (Uterine Fibroids)

full page →AMT-253 →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoBayer AG — avelumab (Phase I/II Trial Completion)avelumab

Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

full page →avelumab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoAbbVie Inc — venetoclax (Phase I/II Trial Completion)venetoclax

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Leukemia, Leukemia, T-Cell Leukemia

full page →venetoclax →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoAstraZeneca Plc — Calquence (Phase I/II Trial Completion)CALQUENCE

Therapy area: Oncology. Indication: CNS Lymphoma, Diffuse Large B-Cell Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma

full page →CALQUENCE →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoHenan Cancer Hospital — methotrexate (Phase I/II Trial Completion)Maxtrex

Therapy area: Oncology. Indication: Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer

full page →Maxtrex →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoArvinas Inc — samuraciclib (Phase I/II Trial Completion)samuraciclib

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

full page →samuraciclib →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoChiba Cancer Center — nivolumab (Phase I/II Trial Completion)nivolumab

Therapy area: Oncology. Indication: Adenoid Squamous Cell Carcinoma (Pseudoglandular Squamous Cell Carcinoma), Basaloid Squamous Cell Carcinoma, Esophageal Cancer, Squamous Cell Carcinoma

full page →nivolumab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoNational Cheng-Kung University Hospital — cisplatin (Phase I/II Trial Completion)cisplatin

Therapy area: Oncology. Indication: Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

full page →cisplatin →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoImplicit Bioscience Ltd — Atibuclimab (Phase I/II Trial Completion)Atibuclimab

Therapy area: Cardiovascular. Indication: Acute Decompensated Heart Failure, Congestive Heart Failure (Heart Failure)

full page →Atibuclimab →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoNakornping Hospital — bupivacaine (Phase I/II Trial Completion)bupivacaine

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 1 2 completion79d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 1 2 initiation79d agoNational Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)PEP-CMV

Therapy area: Oncology. Indication: Ependymoma, Glioma, High-Grade Glioma, Medulloblastoma

full page →PEP-CMV →source: globaldata

Apr 30, 2026phase 1 2 initiation79d agoSichuan Kelun Pharmaceutical Co Ltd — SKB-103 (Phase I/II Trial Initiation)SKB-103

Therapy area: Oncology. Indication: Solid Tumor

full page →SKB-103 →source: globaldata

← prev

page 13 of 147

Week of Apr 27, 2026